Information on 14,625 non-lepromatous patients released from treatment after dapsone monotherapy and fo llowed up to a maximum of 15 years at the ILEP project, Dharmapuri, India, was analysed to study the pattern of relapses. The overall relapse rate was 5/1000 person years. Males had a higher relapse rate than fe males. The risk of relapse increased with age, number oflesions and duration of treatment. The risk for relapse remained constant over several years after release from treatment. Even though the absolute risk for relapse after MDT may be different, the pattern of relapses and the fa ctors affecting it may be similar to what has been shown in this study.
Background information
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The ILEP programme at Dharmapuri was started in 1968 by the Damien Foundation. It was covering a population of I million when the project was handed over to the Government of Tamil Nadu in 1985. Throughout this period the unit had maintained a high level of efficiency in leprosy control work and documentation. The population covered by this unit was essentially rural. The control work was based on the guidelines suggested by the National Leprosy Control Programme. Cases were classified into 'N', 'N?L' and 'L', according to the practice prevalent at that time. 'N' included TT and early BT cases and 'N?L' included the more advanced BT and BB. BL and LL cases were put under 'L'. Apart from this, bacteriologically negative cases with macular lesions were classified as '! , . This probably included a wide range of cases. Polyneuritic cases were classified as 'P'. Until 1971 dapsone was administered in gradually increasing doses up to a maximum of 300 mg per week for adults; children received half that dose. From 1972 this practice of gradually increasing the dose was given up and the maximum dose was increased to 400 mg per week. From 1975 the dose of dapsone was fu rther increased so that the adults received a maximum of 700 mg per week. Patients were declared inactive when the lesions had disappeared, or when a previously raised lesion had become macular or wrinkled in the absence of any evidence of neuritis.
After inactivity, non-lepromatous patients were maintained on the same dose of dapsone for a period of It to 5 years, wherever possible, before being declared as released from treatment (RFT). These patients were indefinitely followed up during the annual 'known case verification'. The treatment cards contained all the relevant information including details regarding relapses. The criteria for relapse were the fo llowing:
(a) Evidence of recurrence of activity in the old lesion; (b) Appearance of a new lesion; (c) Evidence of new nerve involvement.
All relapses were seen and confirmed by a medical officer.
Methodology
All non-lepromatous patients released from treatment from 1968 to 1985 were included in the study. Those who were known to have left the area or died were excluded. The individual treatment cards were reviewed carefully and information regarding personal characteristics, nature and extent of the disease, number of weeks of treatment, date of RFT and date of relapse (if relapsed) were extracted. The duration of treatment was calculated from the information on the number of weeks fo r which treatment was administered to the patients. The information was fed into a computer and analysed using SPSS Pc. Relapse rates were calculated as
No. of relapses x 1000 No. of person years of fo llow-up ' Cases were assumed to have been released from treatment uniformly throughout the year, thus contributing on average half a person year of observation each, during the calender year of RFT. Risk of relapse and cumulative risk for relapse were calculated using the actuarial method. Since cases who had died or left the area were excluded from the study, all the withdrawals were due to censoring caused by the study. Hazard ratios for relapses were calculated based on Cox's proportional hazards model using EGRET.
Results
Of the 14,889 records examined 264 had to be excluded due to incompleteness of information. The remaining 14,625 patients had been fo llowed up for a maximum period of 15 years (mean = 5·2 years; SD = 3·3 years) after RFT. There were 387 relapses during 75,916 ' 5 person years of follow-up giving an overall relapse rate of 5· 1/ I 000 person years.
As shown in Table I the relapse rates were lowest for the 'N' type (4·6/ I 000 per year). 'N?L' and polyneuritic cases had similar relapse rates. Indeterminate cases had the highest relapse rates (24/ 1000). The differences in relapse rates between 'N' and other types were statistically significant (P < 0,05). Relapse rate among males was 80% higher than that among fe males (Table 2) (P < O·OOI). Relapse rates appeared to increase with age at diagnosis until 30 years ( Table 3 ). After that the relapse rate showed a fa ll. A similar trend was noticed when relapse rates were analysed according to age at RFT (Table 4) . Relapse rate tended to increase with duration of treatment (Table 5) . When the relapse rates were examined according to the three different periods with different treatment schedules, no significant differences were noticed (Table 6) .
Relapse rates increased with the number of patches at the time of diagnosis (Table 7) . Graph I shows the cumulative risk of relapse according to the number of patches. For patients with more than 10 patches the probability of relapse by the 7th year was 10%.
The annual risk of relapse after RFT was stable at around 5/1 000 during the first 7 years. There was a slight decrease in the relapse rate after 7 years (Table 8 ). This fa ll is to be expected since there were hardly any cases with more serious fo rms of disease who had been fo llowed up for more than 7 years.
The effect of the number of patches, duration oftreatment and age at diagnosis on the risk· for relapse were examined by doing survival analysis using Cox's proportional hazards model for males and fe males separately (Appendix I & II). The relative risk for relapse increased with the number of patches and duration of treatment as seen in the univariate analysis. However, the relative reduction in the risk for relapse after age 30, seen in the univariate analysis, disappears when adjustments are made for the number of patches and duration of treatment. Thus the risk for relapse tends to increase with the age of the patient at detection. The pattern was similar when age at RFT was entered into the model instead of age at detection. 
Discussion
The annual risk of relapse fo llowing RFT appears to remain steady fo r 7-9 years at about 5 per 1000. Jesudasan I studied relapse rates according to the time after RFT and reported the relapse rates to be about 13/1000 for the first 2 years and about 5/1 000 subsequently.
The design of that study varied from the present one, in that, there was a one time special verification of all RFT cases. Neelan2 had reported that relapse after RFT remained the same over the first 4± years of fo llow-up. This study suggests that the phenomenon of relapse occurs relentlessly for fa irly long periods after releasing from treatment which is incompatible with the concept of median incubation period of 3± years suggested by Pattyn.3 The finding that the males had a higher rate of relapse was similar to what has been reported by Jesudasan. One possible reason for this could be differential surveillance. On the other hand this finding is consistent with the reduced risk of disease and higher rate of remission2 that women seem to enjoy.
The striking association between the risk for relapse and the number of patches is consistent with the findings from other studies.I,2
The effect of age on the relapse rate could be a function of the severity of the disease, since with increasing age at detection the severity also increases incipiently. Similarly the duration of treatment could be a surrogate for severity of disease. Patients whose lesions took a longer time to resolve could have received longer duration of treatment. Thus it appears possible that the duration of time taken for the resolution of lesions may be related to the risk of relapse.
The overall absolute risk fo r relapse per year is only about 5/1 000 in this group and could be considered a conservative estimate. Maintaining all patients under active surveillance may not be cost effective. On the other hand it may be worthwhile fo llowing up individuals with multiple lesions since the risk of relapse is quite high even if they have had prolonged treatment.
Though, these results are based on the analysis of secondary data, they should reflect the load of relapses that occur during routine field work. It is difficult to estimate the proportion of dapsone-resistant cases among them . An average control unit of 400,000 population in a hyperendemic district may have about 10,000 known cases of non lepromatous leprosy, released after treatment with dapsone monotherapy. One should expect to get about 50 cases of relapses annually from this population. Chopra et al.4 reported 21 relapses from among 10,995 patients treated with paucibacillary regime and fo llowed up to a maximum of 4 years. Assuming that this population yielded about 21 ,000 person years of fo llow-up the relapse rate would be about 1/1000 person years of fo il ow up, which is lower than the one shown by this study. The results of our study cannot be directly compared with the information on relapses, obtained from a careful prospective fo llow-up of paucibacillary cases treated with MDT for 6 months. This is because of the difficulties one may face in distinguishing between relapses and reactions and because of the well-known fact that risk for these reactions is higher during the first 2 years after initiation of treatment. In the case of monotherapy most of these events would have occurred during therapy and not after release from treatment. Similarly, freq uent and careful fo llow-up may yield a larger number of events related to changes in the nature and extent of the patches which, probably would be missed, during routine surveillance.
Even though there is a problem of comparing absolute rates of relapses between a historical cohort study and a concurrent cohort study, the pattern of relapses and the factors that modify the risk of relapse are likely to be similar for both those treated with monotherapy and MDT. Further, as shown in this study, the risk of relapse may remain constant over a long period of time after releasing from treatment. Riesgo de recaida en los pacientes no lepromatosos liberados del tratamiento de monoterapia con dapsona
